Clinical Trial Update: Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID) [Phase 3]

View source ↗

Summary

This document provides an update on a Phase 3 clinical trial evaluating BP-SCIG 20% for primary immunodeficiency, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• BP-SCIG 20%

Snippet

Sponsor: Biopharma Plasma LLC | Conditions: Primary Immunodeficiency Diseases | Phase 3 | Status: RECRUITING